GET DAILY SIGNALSJNJ vs LLY: Balancing Steady Healthcare Stability With High-Growth Momentum
Key Takeaways
- Two very different growth profiles: JNJ is a diversified healthcare bellwether posting steady single-digit growth, while LLY is a high-momentum obesity and diabetes leader growing revenue at a much faster clip.
- JNJ's latest quarter was mixed: strong pharmaceutical results were partly offset by sluggish MedTech (medical technology) sales, and management is weighing a spinoff of its orthopedics unit.
- LLY's relative performance has been stronger, driven by surging demand for its GLP-1 (glucagon-like peptide-1) medicines Mounjaro and Zepbound, though pricing pressure remains a watch item.
- Valuation gap is wide: LLY trades at a premium multiple to the sector, while JNJ trades at a more modest valuation with a dividend-oriented profile.
- Momentum versus stability is the central trade-off: LLY offers faster growth and higher volatility, while JNJ offers diversification and steadier cash generation.
Why This Comparison Matters Now
Healthcare investors often weigh two sharply different playbooks when comparing JNJ (Johnson & Johnson) and LLY (Eli Lilly). One is a diversified, 140-year-old healthcare conglomerate spanning pharmaceuticals, medical devices, and consumer staples; the other is a pure-play pharmaceutical company that has become one of the world's largest drugmakers on the back of the obesity and diabetes boom. This stock comparison is relevant to growth-oriented traders evaluating relative performance and to income-focused investors assessing market positioning and stability. Because the two names respond to different catalysts, their recent behavior offers a useful lens on how sentiment is shifting across the broader healthcare sector. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
JNJ's Mixed Quarter and Segment Dynamics
JNJ operates two main segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices and surgical technology). In its most recent quarterly report, total revenue rose 5.9% year over year to $25.4 billion, while adjusted EPS (earnings per share) of $2.59 topped analyst expectations. Growth was concentrated in Innovative Medicine, which advanced 7.7% behind blockbusters such as Tremfya, Darzalex, and Tecvayli. I reviewed the numbers through Tickeron’s AI Trend Prediction Engine for additional context on sector trends.
The quarter also highlighted persistent softness in MedTech, where sales grew only 2.5% and missed forecasts. Management cited geopolitical pressures in the Middle East, European austerity measures, and pricing challenges in China. The company also signaled it is leaning toward a spinoff of its orthopedics division rather than a sale. Despite a raised full-year outlook—adjusted EPS of $11.05 to $11.15 and sales above $100 billion—shares pulled back in recent market activity, reflecting investor caution about the slower-growing device unit.
LLY's Strong Momentum and Pipeline Updates
LLY (Eli Lilly) is a global pharmaceutical company whose recent narrative has been dominated by its incretin-based medicines for diabetes and weight management. In its most recent reported quarter, revenue jumped roughly 48% year over year, led by Mounjaro (up about 91%) and Zepbound (up about 46%). A new oral obesity treatment, Foundayo, began contributing sales, and the company is advancing retatrutide, a next-generation triple-action obesity candidate it expects to file for U.S. Food and Drug Administration (FDA) approval in early 2027.
The company raised its full-year revenue guidance to a range of $85 billion to $87 billion. However, LLY shares have pulled back from recent highs in recent weeks, as investors weighed volume-led growth against realized price declines and competitive and pricing-policy uncertainties. Despite the retreat, analyst sentiment remains broadly positive, with a consensus Buy rating and price targets well above recent trading levels.
Direct Comparison: Growth, Valuation, and Risk
The core contrast between JNJ and LLY is growth versus diversification. LLY is concentrated around a fast-growing metabolic franchise, which fuels rapid revenue expansion but also leaves it more sensitive to pricing policy and competitive dynamics. JNJ spreads risk across two segments and numerous therapeutic areas, generating steadier cash flows but slower top-line growth.
In terms of momentum and relative performance, LLY has delivered superior recent growth, but its forward P/E (price-to-earnings) ratio sits well above the sector average, reflecting higher expectations. JNJ trades at a lower multiple and carries a dividend-focused, more defensive profile. Risk factors differ too: JNJ's near-term overhang is its MedTech underperformance and a potential orthopedics separation, while LLY's is pricing pressure and dependence on a few blockbuster product classes. From what I see, this trade-off remains central for positioning decisions.
Exploring Tickeron AI Trading Bots
I often turn to Tickeron’s Trending AI Robots to review curated strategies that align with current market conditions. The page highlights bots with strong metrics like annualized returns and win rates across different risk profiles and timeframes, helping me match approaches to specific holdings like these two healthcare names. It’s a practical way to explore options without sifting through every available system.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
LLY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for LLY turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 59 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 54%.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 261 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 217 of 298 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (35.624) is slightly higher than the industry average of (-1.421). P/E Ratio (45.360) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement